IMPORTANT NOTE: You may submit your article only through our online submission systemSubmit your manuscript
  • Slider Image

Reviews 2005-2017

Current and Future Options in the Treatment of Malignant Ascites in Ovarian Cancer.
H. WOOPEN, J. SEHOULI (Berlin, Germany). Anticancer Res 29: 3353-3360, 2009.
New Molecular Biomarkers for the Prognosis and Management of Prostate Cancer – The Post PSA Era.
B. BICKERS, C. AUKIM-HASTIE (Portsmouth, Hampshire, UK). Anticancer Res 29: 3289-3298, 2009.
Controversies in the Management of Ovarian Cancer – Pros and Cons for Lymph Node Dissection in Ovarian Cancer.
O. CAMARA, J. SEHOULI (Berlin, Germany). Anticancer Res 29: 2837-2844, 2009.
Pros and Cons of Intraperitoneal Chemotherapy in the Treatment of Epithelial Ovarian Cancer.
A.G. ZEIMET, D. REIMER, A.C. RADL, A. REINTHALLER, C. SCHAUER, E. PETRU, N. CONCIN, S. BRAUN, C. MARTH (Innsbruck; Vienna; Graz, Austria). Anticancer Res 29: 2803- 2808, 2009.
Evidence-based Perioperative Management: Strategic Shifts in Times of Fast Track Surgery.
S.S. CHOPRA, S.C. SCHMIDT, C. FOTOPOULOU, J. SEHOULI, G. SCHUMACHER (Berlin, Germany). Anticancer Res 29: 2799-2802, 2009.
Brain Metastases from Epithelial Ovarian Cancer: Overview and Optimal Management.
K. PIETZNER, G. OSKAY-OEZCELIK, K. EL KHALFAOUI, D. BOEHMER, W. LICHTENEGGER, J. SEHOULI (Berlin, Germany). Anticancer Res 29: 2793-2798, 2009.
Colorectal Cancer and Inflammatory Bowel Disease: Epidemiology, Risk Factors, Mechanisms of Carcinogenesis and Prevention Strategies.
J.K. TRIANTAFILLIDIS, G. NASIOULAS, P.A. KOSMIDIS (Athens, Greece). Anticancer Res 29: 2727-2738, 2009.
Novel Strategy of Anti-angiogenic Therapy for Uterine Cervical Carcinomas.
J. FUJIMOTO (Gifu, Japan). Anticancer Res 29: 2665-2670, 2009.
New Markers and Multivariate Models for Prostate Cancer Detection.
C. STEPHAN, H. RITTENHOUSE, H. CAMMANN, M. LEIN, M. SCHRADER, S. DEGER, K. MILLER, K. JUNG (Berlin, Germany; Diego, CA, USA). Anticancer Res 29: 2589-2600, 2009.
Immunobiological and Experimental Aspects of Malignant Astrocytoma.
R. NANO, E. CAPELLI, A. FACOETTI, E. BENERICETTI (Pavia; Parma, Italy). Anticancer Res 29: 2461-2466, 2009.
Proton Transport Inhibitors as Potentially Selective Anticancer Drugs.
S. HARGUINDEY, J.L. ARRANZ, M.L. WAHL, G. ORIVE, S.J. RESHKIN (Vitoria, Spain; Durham, NC, USA; Bari, Italy). Anticancer Res 29: 2127-2136, 2009.
Heat-shock Protein 90 (Hsp90) as a Molecular Target for Therapy of Gastrointestinal Cancer.
C. MOSER, S.A. LANG, O. STOELTZING (Regensburg; Mainz, Germany). Anticancer Res 29: 2031-2042, 2009.
Tissue Transglutaminase Promotes or Suppresses Tumors Depending on Cell Context.
A. CHHABRA, A. VERMA, K. MEHTA (Houston, TX, USA). Anticancer Res 29: 1909-1920, 2009.
Molecular Imaging of Tumor Blood Vessels in Prostate Cancer.
D. TILKI, M. SEITZ, B.B. SINGER, S. IRMAK, C.G. STIEF, O. REICH, S. ERGÜN (Munich; Essen, Germany; New York, NY, USA). Anticancer Res 29: 1823-1830, 2009.
Cancer-induced Hypercalcemia.
F. LUMACHI, A. BRUNELLO, A. ROMA, U. BASSO (Padova, Italy). Anticancer Res 29: 1551-1556, 2009.
Genetic and Molecular Abnormalities in Cholangiocarcinogenesis.
V.J. HASSID, F.A. ORLANDO, Z.T. AWAD, D. TAN, T. KHOURY, B.H. AHMED, S.J. ALRAWI (Jacksonville; Gainesville, FL; Houston, TX; Buffalo, NY, USA). Anticancer Res 29: 1151-1156, 2009.
Oestrogen-synthesising Enzymes and Breast Cancer.
M. KULENDRAN, M. SALHAB, K. MOKBEL (London; Uxbridge, Middlesex, UK). Anticancer Res 29: 1095-1110, 2009.
RUNX1 Translocations in Malignant Hemopathies.
E. DE BRAEKELEER, C. FÉREC, M. DE BRAEKELEER (Brest, France). Anticancer Res 29: 1031-1038, 2009.
The Role of Toll-like Receptor 2 in Survival Strategies of Mycobacterium tuberculosis in Macrophage Phagosomes.
A. YOSHIDA, H. INAGAWA, C. KOHCHI, T. NISHIZAWA, G.-I. SOMA (Tokushima; Chiba; Yamaguchi; Kagawa, Japan). Anticancer Res 29: 907-910, 2009.
Utility and Safety of LPS-based Fermented Flour Extract as a Macrophage Activator.
Y. TANIGUCHI, N. YOSHIOKA, T. NISHIZAWA, H. INAGAWA, C. KOHCHI, G.-I. SOMA (Tokushima; Kagawa; Yamaguchi; Chiba, Japan). Anticancer Res 29: 859-864, 2009.
Potential for Molecularly Targeted Therapy against Epidermal Growth Factor Receptor Ligands.
S. MIYAMOTO, T. FUKAMI, H. YAGI, M. KUROKI, F. YOTSUMOTO (Fukuoka, Japan). Anticancer Res 29: 823-830, 2009.
ROS and Innate Immunity.
C. KOHCHI, H. INAGAWA, T. NISHIZAWA, G.-I. SOMA (Kagawa- ken; Tokushima-ken; Chibaken; Yamaguchi-ken, Japan). Anticancer Res 29: 817-822, 2009.
High-dose Vitamin C (Ascorbic Acid) Therapy in the Treatment of Patients with Advanced Cancer.
S. OHNO, Y. OHNO, N. SUZUKI, G.-I. SOMA, M. INOUE (Ishikawa; Tokushima; Chiba; Kagawa, Japan). Anticancer Res 29: 809-816, 2009.
Inhibition of Cancer Invasion and Metastasis by Targeting the Molecular Chaperone Heat- shock Protein 90.
F. KOGA, K. KIHARA, L. NECKERS (Tokyo, Japan; Bethesda, MD, USA). Anticancer Res 29: 797-808, 2009.
Genetic Polymorphisms of Smoking-related Carcinogen Detoxifying Enzymes and Head and Neck Cancer Susceptibility.
M. LACKO, M.B. OUDE OPHUIS, W.H.M. PETERS, J.J. MANNI (Maastricht; Nijmegen, The Netherlands). Anticancer Res 29: 753-762, 2009.
Therapy-induced Toxicity of the Lungs: An Overview.
A.G. CHARPIDOU, I. GKIOZOS, S. TSIMPOUKIS, D. APOSTOLAKI, K.D. DILANA, E.M. KARAPANAGIOTOU, K.N. SYRIGOS (Athens, Greece). Anticancer Res 29: 631-640, 2009.
Chronic Lymphocytic Leukaemia.
J. BOELENS, S. LUST, B. VANHOECKE, F. OFFNER (Ghent, Belgium). Anticancer Res 29: 605-616, 2009.
Volume-sensitive Cl– Channel as a Regulator of Acquired Cisplatin Resistance.
T. SHIMIZU, E.L. LEE, T. ISE, Y. OKADA (Okazaki, Japan). Anticancer Res 28: 75-84, 2008.
Confocal Endomicroscopy: In Vivo Diagnosis of Neoplastic Lesions of the Gastrointestinal Tract.
M. GOETZ, R. KIESSLICH (Mainz, Germany). Anticancer Res 28: 353-360, 2008.
The ATM Gene and Ataxia Telangiectasia.
A. MAVROU, G.T. TSANGARIS, E. ROMA, A. KOLIALEXI (Athens, Greece). Anticancer Res 28: 401-406, 2008.
DNA Image Cytometry in Bladder Cancer: State of the Art.
C.A. PALMEIRA, P.A. OLIVEIRA, F. SEIXAS, M.A. PIRES, C. LOPES, L. SANTOS (Porto; Vila Real, Portugal). Anticancer Res 28: 443- 450, 2008.
Human Papillomavirus Accounts both for Increased Incidence and Better Prognosis in Tonsillar Cancer.
H. DAHLSTRAND, A. NÄSMAN, M. ROMANITAN, D. LINDQUIST, T. RAMQVIST, T. DALIANIS (Stockholm, Sweden). Anticancer Res 28: 1133-1138, 2008.
The Role of Regulatory T Cells in Malignant Glioma.
A.M. SONABEND, C.E. ROLLE, M.S. LESNIAK (Chicago, IL, USA). Anticancer Res 28: 1143-1150, 2008.
Update on Molecular Pathology in Oral Cancer and Precancer.
Chemotherapy in Gastric Cancer.
E. WÖLL, A. DEVRIES, W. EISTERER, M. HEJNA, F. KEIL, H. STEIN, J. ZACHERL, R. GREIL (Zams; Feldkirch; Innsbruck; Vienna; Leoben; Salzbuirg, Austria). Anticancer Res 28: 1213-1220, 2008.
Taxanes and Gemcitabine Doublets in the Management of HER-2 Negative Metastatic Breast Cancer: Towards Optimization of Association and Schedule.
Present Treatment and Future Expectations in Advanced Pancreatic Cancer.
G.P. STATHOPOULOS, N. ANDROULAKIS, J. SOUGLAKOS, J. STATHOPOULOS, V. GEORGOULIAS (Athens; Heraklion, Greece). Anticancer Res 28: 1303-1308, 2008.
Inherited Cancer Predisposition Syndromes in Greece.
A. APESSOS, E. PAPADOPOULOU, I. BELOGIANNI, S. BARATSIS, J.K. TRIANTAFILLIDIS, P. KOSMIDIS, E. KARYDAS, E. BRIASOULIS, C. PISIOTIS, K. PAPAZISIS, G. NASIOULAS (Maroussi, Athens; Ioannina; Thessaloniki, Greece). Anticancer Res 28: 1341-1348, 2008.
Biological Activity and Clinical Implications of the Matrix Metalloproteinases.
M. RYDLOVA, L. HOLUBEC Jr., M. LUDVIKOVA Jr., D. KALFERT, J. FRANEKOVA, C. POVYSIL, M. LUDVIKOVA (Ostrava; Plzen; Hradec Kra’lovι; Prague, Czech Republic). Anticancer Res 28: 1389-1398, 2008.
The Biological Relevance of FHL2 in Tumour Cells and its Role as a Putative Cancer Target.
K. KLEIBER, K. STREBHARDT, B.T. MARTIN (Frankfurt, Germany). Anticancer Res 27: 55-62, 2007.
Comparative Biology of Human and Canine Osteosarcoma.
F. MUELLER, B. FUCHS, B. KASER- HOTZ (Zürich, Switzerland). Anticancer Res 27: 155-164, 2007.
Apoptosis in Brain Tumors: Prognostic and Therapeutic Considerations.
M. MELLAI, D. SCHIFFER (Vercelli, Italy). Anticancer Res 27: 437-448, 2007.
The Role of Epoetin Beta in the Treatment of Anaemia in Patients with Gynaecological Malignancies.
P. CORNES, I. BOIANGIU (Bristol, UK). Anticancer Res 27: 513-522, 2007.
Actual Chemotherapeutical Possibilities in Hormone-refractory Prostate Cancer (HRPC) Patients.
D. PREZIOSO, R. GALASSO, M. DI MARTINO, G. IAPICCA, E. ANNUNZIATA, F. IACONO (Naples, Italy). Anticancer Res 27: 1095-1104, 2007.
Cancer Treatment-induced Oral Mucositis.
D. ALTERIO, B.A. JERECZEK.-FOSSA, M.R. FIORE, G. PIPERNO, M. ANSARIN, R. ORECCHIA (Milan, Italy). Anticancer Res 27: 1105-1126, 2007.
Applications of Quantitative Pharmacodynamic Effect Markers in Drug Target Identification and Therapy Development.
R.M. STRAUBINGER, W. KRZYZANSKI, C.M. FRANCOFORTE, J. QU (Amherst, NY, USA). Anticancer Res 27: 1237-1246, 2007.
Proteomic Approaches for Serum Biomarker Discovery in Cancer.
P. MAURYA, P. MELEADY, P. DOWLING, M. CLYNES (Dublin, Ireland). Anticancer Res 27: 1247-1256, 2007.
Extracellular Nucleic Acids and their Potential as Diagnostic, Prognostic and Predictive Biomarkers.
L. O'DRISCOLL (Dublin, Ireland). Anticancer Res 27: 1257-1266, 2007.
The Pharmacology of Cancer Resistance.
R. O'CONNOR (Dublin, Ireland). Anticancer Res 27: 1267-1272, 2007.
Clinical Applications of Expression Profiling and Proteomics in Prostate Cancer.
J.R.W. MASTERS (London, UK). Anticancer Res 27: 1273-1276, 2007.
Page: 1 2 3 4 5 6 ... 7 8 9 10 
Custom Tables Plugin 05a1a29bdcae7b12229e651a9fd48b11

IMPORTANT NOTE: You may submit your article only through our online submission system